Tags : Solid Tumors

IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid

Shots: The companies have expanded their clinical trial collaboration and supply agreement for IDE196 and crizotinib. The study will evaluate combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including MUM, skin melanoma, lung cancer, and colorectal cancer The two global companies have established JDC and there will be joint decision […]Read More

MSD Signs a Clinical Trial Collaboration with Ascentage Pharma for

Shots: Ascentage will be responsible to sponsor the P-Ib/II trial (NCT03611868) which involves assessing of APG-115 in combination with Keytruda, to evaluate its safety and efficacy in solid tumors (i,e., NSCLC, melanoma, Urothelial cancer, Liposarcoma, MPNST and ATM mutated/p53 WT tumors resistant or relapsed to PD-1/PD-L1 treatment or without previous PD-1/PD-L1 treatment) The companies will […]Read More

BioInvent Reports the Enrollment of First Patient in P-I/IIa Study

Shots: The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda, characterizing PK/PD profile and to determine the recommended dose of the combination regimen The study is divided into two parts into Part A, a dose escalation of BI-1206 in combination with the standard dose of […]Read More

Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib

Shots: The two companies collaborated to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib and fruquintinib, with BeiGene’s tislelizumab against multiple solid tumor cancer indications in the US, EU, China and Australia. Both the companies will mutually supply drug and other support Tislelizumab is an anti PD-1 mAb, specifically designed to minimize binding to […]Read More

IDEAYA and Pfizer Collaborate to Evaluate IDE196 + Binimetinib in

Shots: The companies entered into a clinical trial collaboration and supply agreement to evaluate the combination of IDE196 + binimetinib for GNAQ or GNA11 hotspot mutated solid tumors, including MUM, CM & CRC. The study is expected to be initiated in mid-2020 The clinical study will assess whether inhibition of the MAP-Kinase pathway at two […]Read More

Exelixis Signs a Clinical Trial Collaboration with Roche for Patients

Shots: The companies will co-fund the clinical trial which is expected to include three P-III trials for advanced non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC) and renal cell carcinoma (RCC) The focus of the collaboration is to evaluate Exelixis’ Cabometyx (cabozantinib) with Roche’s Tecentriq (atezolizumab) in patients with locally advanced or metastatic solid […]Read More

iTeos Therapeutics Collaborates with Merck to Evaluate EOS100850 + Keytruda

Shots: The companies collaborate to initiate P-I/II study assessing the combination of iTeos’ EOS100850 and Merck’s Keytruda (pembrolizumab) for patients with solid tumors. The companies plan the onset of the study in H1’20 The focus of the study is to determine the safety and tolerability of the combination regimen in solid tumors EOS100850 is a […]Read More

BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with

Shots: In July’2019, Bioinvent reports the FDA’s acceptance of its IND application of BI-1206 + Keytruda combination therapy based on the preclinical data demonstrating that BI-1206 enhances anti-tumor immune responses in patients with solid tumors BioInvent will evaluate the combination therapy in P-I/IIa study in patients with an advanced solid tumor, prior treated with anti-PD1 […]Read More